Home Newsfeeds Morgan Stanley Maintains Equal-Weight on SolarEdge Technologies, Raises Price Target to $352

Morgan Stanley Maintains Equal-Weight on SolarEdge Technologies, Raises Price Target to $352

Morgan Stanley analyst Stephen Byrd maintains SolarEdge Technologies (NASDAQ:SEDG) with a Equal-Weight and raises the price target from $316 to $352.

byBenzinga Newsdesk

August 18, 2022

1 minute read

Morgan Stanley analyst Stephen Byrd maintains SolarEdge Technologies (NASDAQ:SEDG) with a Equal-Weight and raises the price target from $316 to $352.

Deutsche Bank Maintains Sell on Scorpio Tankers, Raises Price Target to $34

By Benzinga Newsdesk

September 6, 9:27 AM

Deutsche Bank analyst Amit Mehrotra maintains Scorpio Tankers (NYSE:STNG) with a Sell and raises the price target from $10.5 to $34.

STNG

Canopy Growth & Martha Stewart CBD Brand Being Sued By Oregon Edibles Producer For Copyright Infringement

By Jelena Martinovic

September 16, 10:17 AM

Canopy Growth Corp. (TSX: WEED) (NASDAQ: CGC) and Martha Stewart Living Omnimedia - based in New York and owned by Marquee Brands - are being sued by Northwest Natural Goods for a copyright and trade dress infringement, reported Marijuana Business Daily.

CGC

Why Department Store Major Macy’s Shares Are Shooting Higher Today

By Shivani Kumaresan

November 16, 10:56 AM

Department store chain Macy's Inc (NYSE: M) shares are surging today after it reported third-quarter FY23 earnings.

Analyst Ratings

Expert Ratings for Checkpoint Therapeutics

By Benzinga Insights

August 15, 4:00 PM

Checkpoint Therapeutics (NASDAQ:CKPT) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

CKPT

Morgan Stanley Maintains Equal-Weight on SolarEdge Technologies, Raises Price Target to $352

Related Posts

Deutsche Bank Maintains Sell on Scorpio Tankers, Raises Price Target to $34

Canopy Growth & Martha Stewart CBD Brand Being Sued By Oregon Edibles Producer For Copyright Infringement

Why Department Store Major Macy’s Shares Are Shooting Higher Today

Expert Ratings for Checkpoint Therapeutics